Oncovista Innovative Therapies Stock Total Asset
| OVIT Stock | USD 0.0001 0.0001 50.00% |
OncoVista Innovative Therapies fundamentals help investors to digest information that contributes to OncoVista Innovative's financial success or failures. It also enables traders to predict the movement of OncoVista Pink Sheet. The fundamental analysis module provides a way to measure OncoVista Innovative's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OncoVista Innovative pink sheet.
OncoVista |
OncoVista Innovative Therapies Company Total Asset Analysis
OncoVista Innovative's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current OncoVista Innovative Total Asset | 12.51 K |
Most of OncoVista Innovative's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OncoVista Innovative Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, OncoVista Innovative Therapies has a Total Asset of 12.51 K. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The total asset for all United States stocks is 100.0% higher than that of the company.
OncoVista Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OncoVista Innovative's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of OncoVista Innovative could also be used in its relative valuation, which is a method of valuing OncoVista Innovative by comparing valuation metrics of similar companies.OncoVista Innovative is currently under evaluation in total asset category among its peers.
OncoVista Fundamentals
| Return On Asset | -23.58 | |||
| Current Valuation | 852.92 K | |||
| Shares Outstanding | 23.56 M | |||
| Price To Earning | (0.12) X | |||
| Price To Book | 26.09 X | |||
| EBITDA | (3.4 M) | |||
| Net Income | (2.54 M) | |||
| Cash And Equivalents | 61.27 K | |||
| Total Debt | 479.3 K | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.28) X | |||
| Cash Flow From Operations | (232.38 K) | |||
| Earnings Per Share | (0.15) X | |||
| Beta | -51.97 | |||
| Market Capitalization | 558.34 K | |||
| Total Asset | 12.51 K | |||
| Retained Earnings | (27.6 M) | |||
| Working Capital | (5.89 M) | |||
| Current Asset | 61 K | |||
| Current Liabilities | 5.95 M | |||
| Net Asset | 12.51 K |
About OncoVista Innovative Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OncoVista Innovative Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OncoVista Innovative using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OncoVista Innovative Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for OncoVista Pink Sheet Analysis
When running OncoVista Innovative's price analysis, check to measure OncoVista Innovative's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoVista Innovative is operating at the current time. Most of OncoVista Innovative's value examination focuses on studying past and present price action to predict the probability of OncoVista Innovative's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoVista Innovative's price. Additionally, you may evaluate how the addition of OncoVista Innovative to your portfolios can decrease your overall portfolio volatility.